While some shareholders would regard Deborah's tenure as largely...

While some shareholders would regard Deborah's tenure as largely uneventful - where compound studies have progressed very slowly, the direction of the company has been vague and as CEO she didn't display a strong conviction. 

Those shareholders are ignoring that she also oversaw a massive destruction of the companies market cap and 2 share dilutions.

I wonder if there will be any announcements in her final week, perhaps trying to end on a high note.

Hopefully the next CEO will have had some experience at a successful bio-tech.